Montoya Taylor, MD
Interventional Cardiology · Milwaukee, WINPI 1558523464
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $33,900 of the $47,707 with a category attached, or 71.1%. ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) accounts for 69.0% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2023 at $15,605 and has fallen 97.5% since, to $387 in 2025. Among interventional cardiology clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 217 payments — averaging $219.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$33K
- Abbott$4K
- Boston Scientific$4K
- Penumbra, Inc.$3K
- Abiomed$616
- AstraZeneca$391
- plus $2K from 18 others
What the payments were for
- Speaking & faculty fees$33,90071%
- Travel & lodging$6,38113%
- Food & beverage$7,28915%
- Gifts$1370%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 66 | $32,925 |
| Abbott | 43 | $4,436 |
| Boston Scientific | 44 | $4,266 |
| Penumbra, Inc. | 4 | $3,402 |
| Abiomed | 8 | $616 |
| AstraZeneca | 6 | $391 |
| Johnson & Johnson | 12 | $290 |
| Shockwave Medical, Inc | 2 | $266 |
| Philips North America LLC | 2 | $205 |
| Endologix LLC | 1 | $130 |
| Inari Medical, Inc. | 3 | $122 |
| Amgen | 2 | $115 |
| Stryker | 5 | $107 |
| Livanova USA, Inc. | 2 | $92 |
| Medtronic(2 entities) | 5 | $88 |
| Novartis | 3 | $77 |
| Impulse Dynamics (USA) Inc. | 1 | $60 |
| Pfizer | 2 | $27 |
| Convatec Inc. | 1 | $19 |
| EKOS Corporation | 1 | $19 |
| Cardinal Health 200 LLC | 1 | $15 |
| Cook Medical LLC | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| Teleflex LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$32,039
- Indigo$3,325
- OPTIS$2,053
- VersaCross Large Access Solution$1,003
- VersaCross Access Solution$932
- ROTABLATOR$902
- AMPLATZER AMULET$755
- Impella$388
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$266
- VASCULAR$263
- FARXIGA$225
- GENERAL VASCULAR ACCESS$185
- XIENCE SIERRA$152
- Rotablator Rotational Atherectomy System Console Kit$150
- WATCHMAN Access System$140
- IGT D Peripheral$137
- Ovation$130
- AFX$130
- XARELTO$125
How this compares
$47,707 in reported general payments places this provider in the 90th percentile of 118 interventional cardiology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 51 | $44,571 |
| EntrestoSacubitril/Valsartan | 23 | $25,915 |
| BrilintaTicagrelor | 26 | $18,076 |
| Repatha SureclickEvolocumab | 15 | $13,875 |
| Metoprolol Succinate | 109 | $1,356 |
| Ranolazine ErRanolazine | 11 | $1,077 |
| Atorvastatin Calcium | 109 | $1,032 |
| Rosuvastatin Calcium | 68 | $547 |
| Carvedilol | 58 | $500 |
| ClopidogrelClopidogrel Bisulfate | 70 | $441 |
| Ezetimibe | 30 | $425 |
| Spironolactone | 38 | $422 |
| Lisinopril | 66 | $318 |
| Furosemide | 53 | $255 |
| Valsartan | 13 | $255 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $27 | $44,57151 claims |
| NovartisEntresto | $77 | $25,91523 claims |
| AstraZenecaBrilinta | $391 | $18,07626 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 118 interventional cardiology providers in Wisconsin.
Other interventional cardiology in Milwaukee
- Michael SalingerMilwaukee$216K
- Tanvir BajwaMilwaukee$106K
- Suhail AllaqabandMilwaukee$88K
- Saif AnwaruddinMilwaukee$80K
- Iyad AzzamMilwaukee$60K
- Mina IskanderMilwaukee$41K
- Anna LarosaMilwaukee$38K
- Louie KostopoulosMilwaukee$26K
- Daniel JohnsrudMilwaukee$25K
- Sasanka JayasuriyaMilwaukee$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.